Selective CT for Anticoagulated Head Injured Patients
Launched by DR. KERSTIN DE WIT · May 5, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating a new system to help doctors safely determine whether patients with head injuries who are taking blood thinners (anticoagulants) need a CT scan to check for serious brain injuries. The goal is to develop a reliable set of guidelines that can help identify those who are at low risk of having a traumatic brain injury, allowing some patients to avoid unnecessary imaging and its associated risks.
To participate in this study, you need to be at least 16 years old and have recently sustained a head injury that brought you to the emergency department. Additionally, you must be currently using anticoagulant medications and have had a CT scan during your visit. If you meet these requirements, you can expect to help researchers test both new and existing guidelines to improve care for patients like you. This trial is currently recruiting participants, and everyone's contribution is valuable in enhancing how we manage head injuries in patients on blood thinners.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥16 years
- • Presents to the emergency department after a head injury
- • Patient has a head CT in the emergency department
- • Is a current anticoagulant user
- Exclusion Criteria:
- • Head injury occurred \>48 h before patient's arrival to the emergency department
- • Penetrating head injury
- • Previously enrolled
- • Patient resides outside of the hospital's catchment area
- • Patient was transferred from another emergency department following neuroimaging
- • Patient was not managed by the emergency or trauma physician in the emergency department
- • Leaves the emergency department prior to completion of their medical assessment
About Dr. Kerstin De Wit
Dr. Kerstin de Wit is a distinguished clinical trial sponsor known for her commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical trial design and implementation, Dr. de Wit leads innovative studies that focus on developing new therapies and enhancing existing treatments across various therapeutic areas. Her collaborative approach fosters strong partnerships with research institutions, regulatory bodies, and industry stakeholders, ensuring the highest standards of ethical conduct and scientific rigor. Dr. de Wit’s dedication to patient-centered research and her strategic vision position her as a key contributor to the evolving landscape of clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Ottawa, Ontario, Canada
Hamilton, Ontario, Canada
Montréal, Quebec, Canada
Kingston, Ontario, Canada
Toronto, Ontario, Canada
Québec City, Quebec, Canada
Patients applied
Trial Officials
Kerstin de Wit, MD
Principal Investigator
Queens University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials